Cladribine therapy in refractory celiac disease with aberrant T cells.

Explore this paper's citation graph

Summary

Treatment with 2-CDA in RCD II is feasible, well tolerated, and can induce clinical and histologic improvement as well as a significant decrease of aberrant T cells in a subgroup of patients, albeit it does not prevent EATL development.

Type
article
Published
2006-11-01
Cited by
139
References
39

Keywords

Medicine, Gastroenterology, Internal medicine, Immunophenotyping, Intraepithelial lymphocyte

References

Cited by

Related papers